 |
市場調査レポート
商品コード
1448368
前部ぶどう膜炎治療の世界市場規模、シェア、成長分析：治療別、流通チャネル別 - 産業予測（2024～2031年）Global Anterior Uveitis Treatment Market Size, Share, Growth Analysis, By Treatment(Corticosteroids, Cycloplegic Agents), By Distribution Channel(Hospital, Retail) - Industry Forecast 2024-2031 |
||||||
| 前部ぶどう膜炎治療の世界市場規模、シェア、成長分析：治療別、流通チャネル別 - 産業予測（2024～2031年） |
|
出版日: 2024年03月02日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の前部ぶどう膜炎治療の市場規模は、2022年に3億5,000万米ドルとなり、2023年の3,710億米ドルから、2031年までには5,913億2,000万米ドルに成長し、予測期間中（2024～2031年）のCAGRは6％で成長する見通しです。
前部ぶどう膜炎の症例の急増が拡大の大きな促進力となっており、目のぶどう膜の前方部分の炎症が特徴です。治療には主に副腎皮質ステロイドと免疫抑制剤が用いられ、多くの場合、副腎皮質ステロイド点眼薬が投与されます。さまざまな基礎疾患が前部ぶどう膜炎を誘発し、その有病率の一因となっています。副腎皮質ステロイド薬の処方は、免疫系に影響を及ぼすため、ぶどう膜炎の種類によって異なります。世界の高齢化に伴い、この疾患に対する脆弱性は増しています。ヒュミラの承認に代表される治療法の革新は、意識の高まり、眼感染率、良好な規制環境などの要因とともに、成長を促進すると予想されます。前部ぶどう膜炎に関連する合併症には、眼圧上昇やコルチコステロイド治療に対する潜在的な副作用があり、緑内障や白内障のような疾患につながるため、不可逆的な失明を防ぐための効果的な管理戦略の必要性が強調されています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
前部ぶどう膜炎治療の世界市場：治療別
- 市場概要
- コルチコステロイド
- サイクル麻痺剤
- 抗TNF剤
- 免疫抑制剤
前部ぶどう膜炎治療の世界市場：流通チャネル別
- 市場概要
- 病院
- 小売り
- オンライン薬局
前部ぶどう膜炎治療の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Novartis AG
- Allergan（now part of AbbVie Inc.）
- Bausch Health Companies Inc.
- Santen Pharmaceutical Co., Ltd.
- Alcon Inc.
- EyePoint Pharmaceuticals
- AbbVie Inc.
- Sun Pharmaceutical Industries Ltd.
- Valeant Pharmaceuticals International（now Bausch Health Companies Inc.）
- Hikma Pharmaceuticals PLC
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson
- AbbVie Inc.
- Bausch Health Companies Inc.
- Mylan N.V.
- Akorn Pharmaceuticals
- Ocular Therapeutix, Inc.
- Clearside Biomedical, Inc.
- Topcon Corporation
- Carl Zeiss Meditec AG
Global Anterior Uveitis Treatment Market size was valued at USD 350 million in 2022 and is poised to grow from USD 371 billion in 2023 to USD 591.32 billion by 2031, growing at a CAGR of 6% during the forecast period (2024-2031).
The surge in cases of anterior uveitis is a significant driving force behind its expansion, characterized by inflammation in the front portion of the eye's uvea. Management primarily involves corticosteroids and immunosuppressive agents, often administered through corticosteroid eye drops. Various underlying conditions can trigger anterior uveitis, contributing to its prevalence. Prescription of corticosteroids is contingent upon the type of uveitis due to their impact on the immune system. With an aging global population, the vulnerability to this condition increases. Innovations in treatments, exemplified by Humira's approval, are expected to fuel growth, alongside factors such as heightened awareness, ocular infection rates, and favorable regulatory environments. Complications associated with anterior uveitis include elevated intraocular pressure and potential adverse reactions to corticosteroid treatment, leading to conditions like glaucoma and cataracts, emphasizing the need for effective management strategies to prevent irreversible blindness.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anterior Uveitis Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Anterior Uveitis Treatment Market Segmental Analysis
The global anterior uveitis treatment market is segmented on the basis of treatment, distribution channel, region. By treatment, the market is segmented into corticosteroids, cycloplegic agents, anti-tnf agents, immunosuppressants. By distribution channel, the market is segmented into hospital, retail, online pharmacies. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.
Drivers of the Global Anterior Uveitis Treatment Market
The rising prevalence of anterior uveitis worldwide, along with the expanding elderly population, serves as a key factor propelling market growth. With the disease becoming more widespread, there is a heightened demand for efficient treatment options.
Restraints in the Global Anterior Uveitis Treatment Market
Certain treatment methods, notably corticosteroids, have the potential to induce undesirable outcomes such as elevated intraocular pressure, cataracts, and glaucoma, which can constrain their prolonged application and impact patient adherence.
Market Trends of the Global Anterior Uveitis Treatment Market
Exploring gene therapies offers hope in tackling the underlying triggers of anterior uveitis through the precise targeting of particular genetic mutations or irregularities linked to this condition.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Anterior Uveitis Treatment Market by Treatment
- Market Overview
- Corticosteroids
- Cycloplegic Agents
- Anti-TNF Agents
- Immunosuppressants
Global Anterior Uveitis Treatment Market by Distribution Channel
- Market Overview
- Hospital
- Retail
- Online Pharmacies
Global Anterior Uveitis Treatment Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan (now part of AbbVie Inc.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch Health Companies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Santen Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alcon Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- EyePoint Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Valeant Pharmaceuticals International (now Bausch Health Companies Inc.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch Health Companies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Akorn Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ocular Therapeutix, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Clearside Biomedical, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Topcon Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Carl Zeiss Meditec AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
